Mohammed Akhtar1, Sameera Rashid2, Issam A Al-Bozom1. 1. Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar. 2. Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar. srashid2@hamad.qa.
Abstract
BACKGROUND: Immune checkpoint proteins, especially PD-L1 and PD-1, play a crucial role in controlling the intensity and duration of the immune response, thus preventing the development of autoimmunity. These proteins play a vital role in enabling cancer cells to escape immunity, proliferate and progress. METHODS: This brief review highlights essential points related to testing for immune checkpoint therapy that histopathologists need to know. RESULTS: In recent years, several inhibitors of these proteins have been used to reactivate the immune system to fight cancer. Selection of patients for such therapy requires demonstration of PD-L1 activation on the tumor cells, best done by immunohistochemical staining of the tumor and immune cells using various antibodies with predetermined thresholds. CONCLUSIONS: Immune checkpoint therapy appears to be promising and is rapidly expanding to include a large variety of cancers.
BACKGROUND: Immune checkpoint proteins, especially PD-L1 and PD-1, play a crucial role in controlling the intensity and duration of the immune response, thus preventing the development of autoimmunity. These proteins play a vital role in enabling cancer cells to escape immunity, proliferate and progress. METHODS: This brief review highlights essential points related to testing for immune checkpoint therapy that histopathologists need to know. RESULTS: In recent years, several inhibitors of these proteins have been used to reactivate the immune system to fight cancer. Selection of patients for such therapy requires demonstration of PD-L1 activation on the tumor cells, best done by immunohistochemical staining of the tumor and immune cells using various antibodies with predetermined thresholds. CONCLUSIONS: Immune checkpoint therapy appears to be promising and is rapidly expanding to include a large variety of cancers.
Authors: Emma J de Ruiter; Frans J Mulder; Bregje M Koomen; Ernst-Jan Speel; Mari F C M van den Hout; Reinout H de Roest; Elisabeth Bloemena; Lot A Devriese; Stefan M Willems Journal: Mod Pathol Date: 2020-08-05 Impact factor: 7.842
Authors: Daniel E Millian; Omar A Saldarriaga; Timothy Wanninger; Jared K Burks; Yousef N Rafati; Joseph Gosnell; Heather L Stevenson Journal: Cancers (Basel) Date: 2022-04-07 Impact factor: 6.575
Authors: Paula Dobosz; Przemysław A Stempor; Miguel Ramírez Moreno; Natalia A Bulgakova Journal: Heredity (Edinb) Date: 2022-04-22 Impact factor: 3.832